A global consortium of governmental, non-governmental, academic and global health organizations and investigators have been working together to develop a novel live attenuated OPV type 2 (nOPV2) vaccine candidate, which would be significantly less likely than existing OPV2 to cause VAPP or cVDPV.

The data package generated so far from pre-clinical evaluation on the two nOPV2 vaccine candidate strains suggests that the risks of reversion to neurovirulence associated with these candidates is substantially lower than the risks from Sabin-2. Based on these data, and the public health need of having such a vaccine for use in outbreak response, these candidates will be evaluated in human clinical trials that are taking place in Belgium in 2017.

Related resources